BG63893B1 - Нови модификации на 2-амино-4-(4-флуоробензиламино)- 1-етоксикарбониламинобензен и методи за тяхното получаване - Google Patents

Нови модификации на 2-амино-4-(4-флуоробензиламино)- 1-етоксикарбониламинобензен и методи за тяхното получаване Download PDF

Info

Publication number: BG63893B1
Authority: BG; Bulgaria
Prior art keywords: modification; compound; preparation; solvent; modifications
Prior art date: 1997-01-20

Application number

BG103657A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103657A (en

Inventor

Peter Meisel

Karl-Friedrich Landgraf

Juergen Schaefer

Wilfried Thiel

Matthias Rischer

Alfred Olbrich

Bernhard Kutscher

Original Assignee

Asta Medica Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-20

Filing date

1999-08-10

Publication date

2003-05-30

1999-08-10 Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft

2000-02-29 Publication of BG103657A publication Critical patent/BG103657A/xx

2003-05-30 Publication of BG63893B1 publication Critical patent/BG63893B1/bg

Links

230000004048 modification Effects 0.000 title abstract description 61
238000012986 modification Methods 0.000 title abstract description 61
238000002360 preparation method Methods 0.000 title abstract description 8
238000000034 method Methods 0.000 title abstract description 5
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 abstract 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
150000001875 compounds Chemical class 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
238000002425 crystallisation Methods 0.000 description 11
230000008025 crystallization Effects 0.000 description 11
239000013078 crystal Substances 0.000 description 8
239000000243 solution Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
238000002441 X-ray diffraction Methods 0.000 description 5
238000001938 differential scanning calorimetry curve Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
239000012047 saturated solution Substances 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000012454 non-polar solvent Substances 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
238000010583 slow cooling Methods 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
-1 1-amino-4- (4fluorobenzylamino) -1-ethoxycarbonylaminobenzene Chemical compound 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pain & Pain Management (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

BG103657A 1997-01-20 1999-08-10 Нови модификации на 2-амино-4-(4-флуоробензиламино)- 1-етоксикарбониламинобензен и методи за тяхното получаване BG63893B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19701694A DE19701694A1 (de)	1997-01-20	1997-01-20	Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
PCT/EP1998/000086 WO1998031663A1 (fr)	1997-01-20	1998-01-09	Nouvelles modifications du 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyle-aminobenzene et procedes permettant de preparer ledit compose

Publications (2)

Publication Number	Publication Date
BG103657A BG103657A (en)	2000-02-29
BG63893B1 true BG63893B1 (bg)	2003-05-30

Family

ID=7817756

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103657A BG63893B1 (bg)	1997-01-20	1999-08-10	Нови модификации на 2-амино-4-(4-флуоробензиламино)- 1-етоксикарбониламинобензен и методи за тяхното получаване

Country Status (30)

Country	Link
US (2)	US5914425A (fr)
EP (1)	EP0956281B1 (fr)
JP (1)	JP4138886B2 (fr)
CN (1)	CN1125812C (fr)
AR (1)	AR015349A1 (fr)
AT (1)	ATE222235T1 (fr)
AU (1)	AU730776B2 (fr)
BG (1)	BG63893B1 (fr)
BR (1)	BR9806784A (fr)
CA (3)	CA2632585C (fr)
CZ (1)	CZ301778B6 (fr)
DE (2)	DE19701694A1 (fr)
DK (1)	DK0956281T3 (fr)
EG (1)	EG21239A (fr)
ES (1)	ES2178152T3 (fr)
HU (1)	HU227625B1 (fr)
ID (1)	ID22645A (fr)
IL (1)	IL130384A (fr)
IS (1)	IS2115B (fr)
NO (2)	NO311642B1 (fr)
NZ (1)	NZ336205A (fr)
PL (1)	PL195956B1 (fr)
PT (1)	PT956281E (fr)
RU (1)	RU2186765C2 (fr)
SK (1)	SK285303B6 (fr)
TR (1)	TR199901674T2 (fr)
TW (1)	TW531527B (fr)
UA (1)	UA63937C2 (fr)
WO (1)	WO1998031663A1 (fr)
ZA (1)	ZA98319B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI287984B (en)	2000-10-17	2007-10-11	Wyeth Corp	Pharmaceutical composition for modulating bladder function
US6589986B2 (en)	2000-12-20	2003-07-08	Wyeth	Methods of treating anxiety disorders
AR033095A1 (es) *	2001-04-04	2003-12-03	Wyeth Corp	Metodos para el tratamiento de motilidad gastrica hiperactiva
US20050089559A1 (en) *	2003-10-23	2005-04-28	Istvan Szelenyi	Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) *	2006-06-05	2011-06-14	Valeant Pharmaceuticals International	Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) *	2006-08-18	2008-02-21	Valeant Pharmaceuticals North America	Derivatives of 1,3-diamino benzene as potassium channel modulators
BRPI0716715B1 (pt) *	2006-08-23	2021-07-06	Xenon Pharmaceuticals, Inc	Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8993593B2 (en) *	2006-08-23	2015-03-31	Valeant Pharmaceuticals International	N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) *	2006-10-10	2014-05-13	Valeant Pharmaceuticals International	N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) *	2006-11-28	2011-10-04	Valeant Pharmaceuticals International	1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) *	2007-06-13	2013-02-05	Valeant Pharmaceuticals International	Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en)	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) *	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
AU2009270768A1 (en) *	2008-07-18	2010-01-21	Valeant Pharmaceuticals International	Modified release formulation and methods of use
US20100323016A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
US20100323015A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
DE102009013613A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Trockenverarbeitung von Retigabin
DE102009013611A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
WO2011039369A2 (fr)	2009-10-02	2011-04-07	Medichem S.A.	Formes amorphes d'un dérivé de 2-amino-4-(4-fluorobenzylamino)phénylcarbamate
EP2525788A2 (fr)	2010-01-20	2012-11-28	Glaxo Group Limited	Nouvelle composition du retigabine
WO2011101456A2 (fr) *	2010-02-19	2011-08-25	Medichem S.A.	Dérivé de phénylcarbamate stabilisé à l'état solide
CN202095728U (zh)	2010-10-29	2012-01-04	假日集团控股有限公司	行李箱把手
CN102464233A (zh) *	2010-11-18	2012-05-23	江苏邦威机械制造有限公司	一种卧式差速缠丝机用应力发生装置
SG191309A1 (en)	2011-01-18	2013-07-31	Glaxo Group Ltd	Process for the preparation of retigabine
CN102241608A (zh) *	2011-05-12	2011-11-16	天津市汉康医药生物技术有限公司	瑞替加滨化合物及其组合物
WO2013008250A2 (fr) *	2011-07-01	2013-01-17	Dr.Reddys Laboratories Limited.	Forme cristalline de la rétigabine et procédés de mélange de variétés cristallines de la rétigabine
WO2013011518A1 (fr)	2011-07-21	2013-01-24	Arch Pharmalabs Limited	Procédé de préparation de rétigabine de formule i et de ses sels pharmaceutiquement acceptables
USD696019S1 (en)	2011-10-21	2013-12-24	Travelpro International Inc.	Handle for luggage
CN102531966B (zh) *	2011-12-23	2013-07-24	山东创新药物研发有限公司	瑞替加滨的晶型d及其制备方法
WO2013114379A1 (fr) *	2012-01-30	2013-08-08	Symed Labs Limited	Nouveaux polymorphes d'ester éthylique de l'acide carbamique n-[2-amino-4-(4-fluorobenzylamino)-phényl] et procédés associés
CN103373941B (zh) *	2012-04-11	2016-08-17	浙江九洲药物科技有限公司	瑞替加滨及其中间体的制备方法
WO2013179298A2 (fr) *	2012-04-23	2013-12-05	Cadila Healthcare Limited	Procédé pour la préparation d'un dérivé de phénylcarbamate et de formes polymorphes de celui-ci
WO2014023270A1 (fr)	2012-08-09	2014-02-13	Zentiva, K.S.	Sels ou co-cristaux de n-[2-amino-4-[(4-fluorophényl)méthylamino]-phényl]carbamate d'éthyle
CN102964273B (zh) *	2012-12-06	2014-04-02	北京英科博雅科技有限公司	瑞替加滨的新晶型f及其制备方法
USD773819S1 (en)	2015-05-27	2016-12-13	Travelpro Products, Inc.	Handle for luggage
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
CN114667146A (zh)	2019-11-08	2022-06-24	泽农医药公司	治疗抑郁症的方法
PE20231815A1 (es)	2021-02-09	2023-11-16	Xenon Pharmaceuticals Inc	Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3917113A1 (de) *	1989-05-26	1990-11-29	Schwarzkopf Gmbh Hans	Verfahren zur selektiven herstellung von n(pfeil hoch)4(pfeil hoch)-substituierten 1,4-diamino-2-nitrobenzolen
GB8921792D0 (en) *	1989-09-27	1989-11-08	May & Baker Ltd	New compositions of matter
DE4200259A1 (de) *	1992-01-08	1993-07-15	Asta Medica Ag	Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung

1997
- 1997-01-20 DE DE19701694A patent/DE19701694A1/de not_active Ceased
1998
- 1998-01-09 ID IDW990520A patent/ID22645A/id unknown
- 1998-01-09 ES ES98904048T patent/ES2178152T3/es not_active Expired - Lifetime
- 1998-01-09 HU HU0000944A patent/HU227625B1/hu active Protection Beyond IP Right Term
- 1998-01-09 AU AU62081/98A patent/AU730776B2/en not_active Ceased
- 1998-01-09 DK DK98904048T patent/DK0956281T3/da active
- 1998-01-09 CZ CZ0250899A patent/CZ301778B6/cs not_active IP Right Cessation
- 1998-01-09 BR BR9806784-2A patent/BR9806784A/pt not_active Application Discontinuation
- 1998-01-09 TR TR1999/01674T patent/TR199901674T2/xx unknown
- 1998-01-09 DE DE59805186T patent/DE59805186D1/de not_active Expired - Lifetime
- 1998-01-09 PL PL98335647A patent/PL195956B1/pl unknown
- 1998-01-09 CA CA2632585A patent/CA2632585C/fr not_active Expired - Lifetime
- 1998-01-09 CA CA2634811A patent/CA2634811C/fr not_active Expired - Lifetime
- 1998-01-09 RU RU99118590/04A patent/RU2186765C2/ru not_active IP Right Cessation
- 1998-01-09 PT PT98904048T patent/PT956281E/pt unknown
- 1998-01-09 EP EP98904048A patent/EP0956281B1/fr not_active Expired - Lifetime
- 1998-01-09 JP JP53362698A patent/JP4138886B2/ja not_active Expired - Lifetime
- 1998-01-09 NZ NZ336205A patent/NZ336205A/xx not_active IP Right Cessation
- 1998-01-09 IL IL13038498A patent/IL130384A/xx not_active IP Right Cessation
- 1998-01-09 CN CN98801733A patent/CN1125812C/zh not_active Expired - Lifetime
- 1998-01-09 CA CA002278201A patent/CA2278201C/fr not_active Expired - Lifetime
- 1998-01-09 US US09/004,926 patent/US5914425A/en not_active Expired - Lifetime
- 1998-01-09 AT AT98904048T patent/ATE222235T1/de active
- 1998-01-09 SK SK956-99A patent/SK285303B6/sk not_active IP Right Cessation
- 1998-01-09 WO PCT/EP1998/000086 patent/WO1998031663A1/fr not_active Ceased
- 1998-01-10 EG EG3098A patent/EG21239A/xx active
- 1998-01-15 ZA ZA9800319A patent/ZA98319B/xx unknown
- 1998-01-15 TW TW087100485A patent/TW531527B/zh not_active IP Right Cessation
- 1998-01-20 AR ARP980100249A patent/AR015349A1/es active IP Right Grant
- 1998-09-01 UA UA99084740A patent/UA63937C2/uk unknown
- 1998-10-29 US US09/181,671 patent/US6538151B1/en not_active Expired - Lifetime
1999
- 1999-06-29 IS IS5098A patent/IS2115B/is unknown
- 1999-07-13 NO NO19993452A patent/NO311642B1/no not_active IP Right Cessation
- 1999-08-10 BG BG103657A patent/BG63893B1/bg unknown
2011
- 2011-09-16 NO NO2011017C patent/NO2011017I2/no unknown

Also Published As

Publication number	Publication date
ATE222235T1 (de)	2002-08-15
HUP0000944A2 (hu)	2000-09-28
JP4138886B2 (ja)	2008-08-27
HU227625B1 (en)	2011-09-28
ES2178152T3 (es)	2002-12-16
PT956281E (pt)	2002-12-31
ZA98319B (en)	1998-05-07
CA2632585A1 (fr)	1998-07-23
US5914425A (en)	1999-06-22
DE59805186D1 (de)	2002-09-19
DK0956281T3 (da)	2002-11-04
NO2011017I1 (no)	2011-09-26
EP0956281B1 (fr)	2002-08-14
EP0956281A1 (fr)	1999-11-17
NO311642B1 (no)	2001-12-27
CZ301778B6 (cs)	2010-06-23
CN1125812C (zh)	2003-10-29
SK285303B6 (sk)	2006-10-05
TW531527B (en)	2003-05-11
AR015349A1 (es)	2001-05-02
CZ250899A3 (cs)	1999-11-17
NO993452D0 (no)	1999-07-13
US6538151B1 (en)	2003-03-25
AU6208198A (en)	1998-08-07
RU2186765C2 (ru)	2002-08-10
TR199901674T2 (fr)	1999-10-21
PL335647A1 (en)	2000-05-08
IL130384A0 (en)	2000-06-01
NO2011017I2 (no)	2013-04-02
DE19701694A1 (de)	1998-07-23
CA2632585C (fr)	2010-08-24
SK95699A3 (en)	2000-03-13
IS5098A (is)	1999-06-29
EG21239A (en)	2001-03-31
PL195956B1 (pl)	2007-11-30
CN1243506A (zh)	2000-02-02
ID22645A (id)	1999-12-02
UA63937C2 (uk)	2004-02-16
BR9806784A (pt)	2000-05-02
IL130384A (en)	2003-02-12
CA2278201C (fr)	2009-06-16
HUP0000944A3 (en)	2000-10-30
HK1024230A1 (en)	2000-10-05
AU730776B2 (en)	2001-03-15
IS2115B (is)	2006-06-15
BG103657A (en)	2000-02-29
CA2634811C (fr)	2012-11-20
NZ336205A (en)	2000-01-28
CA2278201A1 (fr)	1998-07-23
CA2634811A1 (fr)	1998-07-23
WO1998031663A1 (fr)	1998-07-23
NO993452L (no)	1999-07-13
JP2001508077A (ja)	2001-06-19

Publication	Publication Date	Title
RU2186765C2 (ru)	2002-08-10	Кристаллические модификации 2-амино-4-(4-фторбензиламино)-1-этоксикарбонил-аминобензола и способ их получения (варианты)
RU2467012C2 (ru)	2012-11-20	Способ очистки стауроспорина и способ получения n-бензоилстауроспорина
CZ364696A3 (en)	1997-07-16	Novel crystalline modification of 1-cyclopropyl-7-(/s,s/-2,8-diazabicyclo/4.3.0/non-8-yl)-6-fluoro- -1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride, process of its preparation and pharmaceutical compositions containing thereof
HUP0102334A2 (hu)	2002-05-29	Paroxetin-metánszulfonát, eljárás az előállítására, valamint a vegyületet tartalmazó gyógyszerkészítmények
CN112142679B (zh)	2023-05-09	一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
KR19990023433A (ko)	1999-03-25	결정 형태의 ｎ-(4-트리플루오로메틸페닐)-5-메틸이소옥사졸-4-카복스아미드
CN114127085A (zh)	2022-03-01	一种肽酰胺盐及其制备方法和在医药上的用途
EP3135666A1 (fr)	2017-03-01	Forme cristalline iii du (s)-oxiracétam, son procédé de préparation, et application
CN109516991B (zh)	2020-08-07	一种枸橼酸托法替尼晶型化合物及其制备方法
EP4574825A1 (fr)	2025-06-25	Forme cristalline de composé ester de pyrazolopyrimidine et son procédé de préparation
JP2022508864A (ja)	2022-01-19	チロシンキナーゼ阻害剤のマレイン酸塩の結晶形及びその調製方法
KR102111247B1 (ko)	2020-05-14	다파글리플로진 무정형 형태의 공결정 또는 복합제
EP4431515A1 (fr)	2024-09-18	Nouvelles formes cristallines d'un composé d'acide borique peptidique et leurs procédés de préparation
CN116332911B (zh)	2023-10-13	嘧啶衍生物1d228的游离碱或盐酸盐与分散剂的共无定型物及其制备方法和应用
JP2707012B2 (ja)	1998-01-28	Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
EP4674850A1 (fr)	2026-01-07	Forme cristalline du composé 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione et son procédé de préparation
EP0367944A2 (fr)	1990-05-16	Dérivés éthérés de 4-[3H]-quinazolinone, procédé pour leur préparation et compositions pharmaceutiques
WO2026046265A1 (fr)	2026-03-05	Chlorhydrate de kéméiflufène et forme cristalline de celui-ci, procédé de préparation et application
TW201908320A (zh)	2019-03-01	一種ｂｔｋ激酶抑制劑的結晶形式及製備方法
CN114437026A (zh)	2022-05-06	一种低组合物杂质的苹果酸奈诺沙星原料药及其制备方法
US7449584B2 (en)	2008-11-11	N-(2((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1
CN118406058A (zh)	2024-07-30	一种替莫唑胺-阿魏酸的药物共晶体及其制备方法
WO2026086730A1 (fr)	2026-04-30	Forme cristalline d'enmétazobactam et son procédé de préparation
JPH05155820A (ja)	1993-06-22	Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
HK1024230B (en)	2004-07-30	Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycai and processes for preparing said compound